Glucose-dependent Insulinotropic Peptide as an Osteotropic Hormone
Glucose-dependent Insulinotropic Peptide (GIP) is synthesized and secreted from endocrine cells in the small intestine, and its role in coupling nutrient intake and insulin secretion is well known. Parathyroid hormone and vitamin D couple calcium intake to bone formation but no coupling hormone has been identified for nutrient intake and bone formation.
This patented invention provides the first evidence that GIP receptors are present in bone and osteoblastic like cells and that GIP modulates the function of these cells. Using a rat model of osteoporosis, the invention demonstrates GIP's anabolic actions on remodeling bone and increasing vertebral bone density. Transgenic mice overexpressing GIP have increased bone density compared to same age controls. GIP or analogs thereof can therefore be used as therapeutic compositions to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.
For more information please contact:
Girish Nallur, Ph.D.
Chief Scientific Officer
Competitive Technologies, Inc.
This email address is protected, Javascript must be enabled to view it
Tel: 203.368.6044
